BioNTech, founded by Turkish immigrants to Germany, and its US partner Pfizer on Tuesday announced starting of clinical study “to evaluate safety tolerability and immunogenicity of an Omicron-based vaccine candidate.” In a statement, the two companies announced the launching of a clinical study saying that it will be carried out on “healthy adults 18 through...
Latest News:
The arms issue
What matters on Thursday, February 3
Everyone plays a waiting game
What matters on Wednesday, February 1
Six-party opposition roundtable announces the Common Policies Text
Expensive export and cheap import records were broken
What matters on Tuesday, January 31
Economic confidence on the rise
What matters on Monday, January 30
What matters on Friday, January 27
Macroprudential measures can’t replace monetary policy: TUSIAD
Digital transformation of Chinese commercial banks: OPINION
The sustainable advantages of purchasing second-hand products
It’ll be enough to manage until the election!
What matters on Wednesday, January 25
Startups receive USD 1.6bn funding in 2022
Domestic tourism expenditures skyrocket
Consumer confidence hits 16-month high
What matters on Monday, January 23
Home
Pfizer
Tag: Pfizer
Fourth mRNA booster does not fully protect against omicron
The mRNA vaccine booster shots from Pfizer-BioNTech or Moderna are partially effective in defending against the Omicron variant of the coronavirus. They are safe and produce substantial antibodies, according to the preliminary results of research conducted by Sheba Medical Center in Israel. The trial showed that one week after people received the booster shot from...